More recently, both umbilical cord–derived biologics and exosome-based products have been explored in allogeneic (non-autologous) settings, where the biologic material originates from a donor rather than the patient. Exosomes—cell-derived extracellular vesicles involved in cellular communication—have become an area of growing interest due to their signaling properties and potential role in supporting tissue environment modulation. As research continues to evolve, the range of clinical applications being studied for these biologics has expanded across multiple areas of medicine.

While many of these allogeneic and exosome-based applications are not specifically FDA-approved for particular indications, they are subject to regulatory oversight. In clinical practice, licensed providers are responsible for evaluating patient appropriateness, obtaining informed consent, and determining how these therapies may be incorporated into physician-directed care based on current evidence, clinical judgment, and applicable regulatory frameworks.

DISCLAIMER: None of the therapies mentioned here have been evaluated or approved by the FDA. As with any medical procedure, Vitalgenics and its practitioners do not guarantee any specific outcome or result. No protocol or specific biologic indication has been evaluated or approved by the FDA.